- Home
- IMTE vs QLGN Comparison
IMTE vs QLGN Comparison
Compare IMTE & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTE
- QLGN
- Stock Information
- Founded
- IMTE 2008
- QLGN 1996
- Country
- IMTE Malaysia
- QLGN United States
- Employees
- IMTE N/A
- QLGN N/A
- Industry
- IMTE Consumer Electronics/Appliances
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- IMTE Consumer Staples
- QLGN Health Care
- Exchange
- IMTE Nasdaq
- QLGN Nasdaq
- Market Cap
- IMTE 3.3M
- QLGN 3.1M
- IPO Year
- IMTE N/A
- QLGN N/A
- Fundamental
- Price
- IMTE $1.00
- QLGN $1.86
- Analyst Decision
- IMTE
- QLGN
- Analyst Count
- IMTE 0
- QLGN 0
- Target Price
- IMTE N/A
- QLGN N/A
- AVG Volume (30 Days)
- IMTE 30.5K
- QLGN 93.1K
- Earning Date
- IMTE 10-21-2025
- QLGN 08-14-2025
- Dividend Yield
- IMTE N/A
- QLGN N/A
- EPS Growth
- IMTE N/A
- QLGN N/A
- EPS
- IMTE N/A
- QLGN N/A
- Revenue
- IMTE $123,337.00
- QLGN N/A
- Revenue This Year
- IMTE N/A
- QLGN N/A
- Revenue Next Year
- IMTE N/A
- QLGN N/A
- P/E Ratio
- IMTE N/A
- QLGN N/A
- Revenue Growth
- IMTE 4.75
- QLGN N/A
- 52 Week Low
- IMTE $0.51
- QLGN $1.61
- 52 Week High
- IMTE $3.17
- QLGN $10.84
- Technical
- Relative Strength Index (RSI)
- IMTE 46.33
- QLGN 32.69
- Support Level
- IMTE $0.92
- QLGN $1.82
- Resistance Level
- IMTE $1.02
- QLGN $2.09
- Average True Range (ATR)
- IMTE 0.06
- QLGN 0.14
- MACD
- IMTE 0.00
- QLGN 0.05
- Stochastic Oscillator
- IMTE 45.71
- QLGN 52.08
About IMTE Integrated Media Technology Limited
Integrated Media Technology Ltd is engaged in the development, sale, and distribution of autostereoscopic 3D display, 3D conversion equipment, and software, development, and sale of 3D autostereoscopic technology, and the provision of 3D consultancy services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.